Barely Significant
← all excerpts

Trends in <i>Pseudomonas aeruginosa</i> In Vitro Susceptibility to Ceftolozane/Tazobactam in Latin America: SMART Surveillance Program, 2016-2024.

Antibiotics (Basel) · 2025 · PMC12562063 · PMID 41148710

Europe PMCDOI
3
hedged sentences
0.0001
closest p · 0.0× alpha
0.0390
boldest claim

The sentences

showed a trendp < 0.0001actually significant
Significant variation ( p < 0.05) in annual ceftolozane/tazobactam percent susceptible values was not observed for isolates from blood, intra-abdominal, and respiratory tract sources, while isolates from urine showed a trend of increasing ceftolozane/tazobactam susceptibility from 73.1% (2018, n = 145) to 90.6% (2023, n = 117) ( p < 0.0001).

also in 33,237 other papers

a decreasing trendp = 0.039actually significant
DTR percentages were highest in 2016 (15.8%) and lowest in 2023 (12.2%), with a decreasing trend ( p = 0.039).

also in 29,529 other papers

a significant trendno p-value reported
Among the countries that participated in SMART each year from 2016 to 2024, three (Argentina, Chile, and Panama) exhibited a significant trend of increasing susceptibility to ceftolozane/tazobactam ( Figure 4 A).

also in 6,185 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.